Joseph W. Turek, MD, PhD Joseph W. Turek, MD, PhD

Joseph W. Turek, MD, PhD

Heart Surgeon, Pediatric Heart Surgeon

No ratings available.
question Circle Img
Duke Health Provider What's this?
Insurance

Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below. Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy

Click to see a list of accepted insurance plansHide accepted insurance plans
Contact
919-681-2343 Office number
919-681-4907
Fax number
Insurance

Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below. Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy

Click to see a list of accepted insurance plansHide accepted insurance plans

Contact
WHERE I PROVIDE CARE
Profile
ABOUT ME

I am the chief of pediatric heart surgery at Duke Health. Being a heart surgeon was always a dream of mine as a child. Spending a summer in medical school with legendary pediatric heart surgeon, Aldo Castaneda, cemented my desire to devote my life to this profession. Clinically, I love the creativity, complexity and challenge associated with my work. I am also able to satisfy my investigational curiosities through an active basic and clinical research laboratory focusing on congenital heart disease. I consider myself extremely lucky to be able to fulfill this dream back at Duke, a place that was so influential in my surgical training. Outside the hospital, I most enjoy spending time with my wife of 20+ years and three young children. We are an active family, always on the go… which mirrors my life at work.

School of Medicine Department
School of Medicine Division
LANGUAGES I SPEAK
English
Training
EDUCATION
MD, University of Illinois College of Medicine at Chicago, 2002
PhD, University of Illinois at Chicago, 2002
RESIDENCY
General Surgery, Duke University Medical Center, 2002-2007
FELLOWSHIP
Cardiothoracic Surgery, Duke University Medical Center, 2007-2010
Congenital Heart Surgery, Visiting Fellow, Texas Children's Hospital, 2010
Congenital Heart Surgery, Children's Hospital of Philadelphia (Pennsylvania), 2010-2011
BOARD CERTIFICATION
American Board of Thoracic Surgery, Congenital Cardiac Surgery
American Board of Thoracic Surgery, Cardiothoracic Surgery
American Board of Surgery, Surgery
Clinical Focus and Research
MY RESEARCH INTERESTS

My research focuses on understanding a new mechanism by which the aorta enlarges in a life-threatening manner in patients with Marfan syndrome (MFS). MFS is a genetic condition that predisposes to aortic enlargement, or aneurysm, that can lead to life-threatening rupture or tearing of the vessel. I am currently investigating a new pathway which appears to contribute to aneurysms in this genetic condition. I have developed a model of accelerated aneurysm growth in mice genetically engineered to have MFS. All of these mice form significant aneurysms in just two weeks. When these mice are treated with the drug (Losartan) currently used in human MFS patients to prevent aneurysm growth, aortic growth is slowed, yet still present. Importantly, adding a second drug to the treatment regimen (which blocks a different receptor protein). It is my objective to understand new mechanisms by which aortic enlargement progresses in patients with MFS. This knowledge has the potential to reveal unique therapeutic targets to combat the devastating aortic pathology in MFS. I feel the most effective future therapy for our MFS patients will involve multi-drug regimens targeting these important alternate signaling pathways.

PUBLICATIONS
View Joseph Turek's publications on PubMed
Industry Relationships and Collaborations
This faculty member has no reported relationships with industry.